Cancer
Conditions
Keywords
Cancer, Cachexia, Nutritional status, Tube feeding, PCNF
Brief summary
Many studies (including ASPEN/ESPEN) have demonstrated that balanced diet formula rich in omega 3 fatty acids (ω-3 FA), fibers, protein as well as mineral, vitamins (trace elements) are essential for cancer patients to improve health status and tolerability of chemotherapy. Hence, the present multi-centered, randomized clinical trial was framed to evaluate the efficacy of ready to use balanced nutritional formula-PCNF (rich in ω-3 FA, fibers, MTC, BCAA, and micro-nutrients), in various cancer patient by checking calorie intake and overall health status through assessing various anthropometric and biochemical parameters especially total proteins, pre-albumin, and transferrin.
Detailed description
Many studies (including ASPEN/ESPEN) have demonstrated that balanced diet formula rich in omega 3 fatty acids (ω-3 FA), fibers, protein as well as mineral, vitamins (trace elements) are essential for cancer patients to improve health status and tolerability of chemotherapy. Hence, oncologic nutritionist strongly recommends cancer patients (with cachexia) to consume a diet rich in protein and dietary fibers along with balanced essential micronutrients like vitamins and minerals (Van Norren et al., 2009; Yeh et al., 2013). From the above statement, it cleared that nutritional support is a crucial aspect of multi-modal cancer care, by improving the overall health status by suppressing various adverse events as well as enhance treatment regimen for a speedy recovery. Hence, the present multi-centered, randomized clinical trial was framed to evaluate the efficacy of ready to use balanced nutritional formula-PCNF (rich in ω-3 FA, fibers, MTC, BCAA, and micro-nutrients), in various cancer patient by checking calorie intake and overall health status through assessing various anthropometric and biochemical parameters especially total proteins, pre-albumin, and transferrin.
Interventions
DIETARY_SUPPLEMENTProtison cancer nutritional formula (PCNF)
PCNF (237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
Sponsors
Chung Shan Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
None, since treating cancer patients
Intervention model description
Supplementation with the commercial nutritional formula (PCNF; 237 mL/Pack) for 5-6 times/day via bolus NG tube feeding for 12 weeks
Eligibility
Sex/Gender
ALL
Age
55 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
* only hospitalized cancer patients with risk of malnutrition and underweight (confirmed with BMI, protein, and pre-albumin level) and must be under NG tube feeding.
Exclusion criteria
* avoiding cancer patients under critical conditions, with cardiac, renal, and hepatic disorders. Also, heavy smokers, chronic or chain smokers, and pregnant/lactating women were not included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Calorie intake | 12 weeks | The mean value of calorie intake (energy) were significantly increased in PCNF supplemented subjects |
| Anthropometric parameters | 12 weeks | BMI were markedly improved in PCNF intook subjects |
| Protein nutritional assessment index or nutritional status | 12 weeks | Protein nutritional assessment index (total protein, pre-albumin , and transferrin) were significantly improved |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glycemic indices | 12 weeks | No significant changes in any of the glycemic indices or lipid profile PCNF groups |
Countries
Taiwan
Outcome results
None listed